Wednesday, May 1, 2013

Upcoming meeting: Tumor Models, Boston, July 23-25, 2013

Better Preclinical Models. Better Predictions. Better Patient Response.

Tumor Models gives you the tools to develop and utilize the very best preclinical oncology models. 
This is a meeting for drug developers who are looking for answers to the difficulties faced with preclinical oncology models that are currently being used to test new cancer drugs. This is a forum to learn what you really need to know about the models pharma are using that are superior in predicting efficacy and mimicking tumor activity in patients. It’s also the best way to identify what preclinical questions need to be answered and make the best possible translational decisions. Decisions that will lead to more effective drug performance in the clinic. 


Napoleone Ferrara
Distinguished Professor, UC San Diego
Napoleone is credited with identifying the human VEGF gene and describing its proangiogenic properties, which formed the basis for the development of Genentech’s bevacizumab. In 2013 he was awarded the $3 million Breakthrough Prize in Life Sciences for his work

Anderson Clark
Director of in vivo Pharmacology, EMD Serono

Richard Gregory
Laboratory Head, Sanofi

Frank Gibbons
Principal Scientist, AstraZeneca

Arijit Chakravarti
Senior Scientist, Millennium Pharmaceuticals

Pasquale Cirone
Postdoctoral Fellow, Pfizer

Brant Firestone
Senior Research Investigator, Novartis

Jonathan Fitzgerald
Senior Director, Merrimack Pharmaceuticals
Jonathan leads the pre-POC team for MM-398, liposomal irinotecan, charged with the 

Ching Ching Leow
Senior Scientist, MedImmune

Vihren Kolev
Scientist, Verastem

Kevin Leong
Scientist, Genentech

Sharon McGonigle
Principle Scientist, Eisai

Glenn Merlino
Head of Cancer Modeling, NIH

Jennifer Michaelson
Director of Research, Jounce Therapeutics

George Naumov
Senior Research Biologist, Merck

Thomas Seyfried
Professor of Biology, Boston College

Birgit Schultes
Senior Research Director, Momenta Pharmaceuticals

Dhaval Shah
Senior Scientist, Pfizer

Terri Van Dyke
Head of Cancer Pathways & Mechanisms, NIH
Terry, a leader in the use and study of genetically modified mice to model human disease, serves as Chief of the Mouse Cancer Genetics Program and Director of the Center for Advanced Preclinical Research at the NCI.

Li Yu
Research Director, Roche
Li has worked as a Research Director and DMPK expert at Hoffmann-La Roche. She has contributed to many oncology programs from discovery to final registration including VELCADE, ZELBORAF and Obinutuzumab.

Jianguo Ma
Associate Director, EMD Serono

Kuan-chun Huang
Scientist, Eisai

Jan Pinkas
Director, ImmunoGen

Michael Luther
Corporate Vice President
Global Discovery Research Services, Charles River Laboratories



No comments:

Post a Comment